InvestorsHub Logo
icon url

geocappy1

06/09/13 11:46 AM

#126793 RE: md1225 #126791

Disagree. Based on what FTM said we need to be 20% better than the control group. For cosmetic view, it would be beneficial to be 20% better then control group and better than the 12.3 months Avastin reached.
icon url

investingdog

06/09/13 12:09 PM

#126796 RE: md1225 #126791

<<We need 13.3 months mos minimum on frontline trial that's 4 weeks longer then the Avastin results>>

Well, this is from your link on Avastin trial. Is MOS 16.5?? What' wrong here?

"To date, 27 patients (68%) have had documented disease progression and 23 patients (58%) have died. Five patients (13%) are still on active treatment. The median progression-free survival was 7.9 months (95% CI, 6.0-11.1) (Fig. 1), indicating a statistically significant improvement over the historical control (evidenced by the lower boundary of the confidence interval above the historical median progression-free survival mark of 4.5 months). Median overall survival was 16.5 months (95% CI, 13.6-31.2) (Fig. 1)."